November 12 Product: Intercept Pharmaceuticals Ocaliva Indication: Primary biliary cholangitis After initially delaying its decision last month, the FDA on Tuesday declined to give Intercept Pharmaceuticals Ocaliva (obeticholic acid) full approval for primary biliary cholangitis (PBC)
Based on glutathione's role in the body, this formula is intended to support a healthy glutathione status, promote antioxidant status, support normal immune function, and support the liver's normal detoxification pathways, including the body's normal clearance of heavy metals.* It's worth being realistic here: this is a support product, not a fix
The catch: being overweight alone probably will not qualify
Such databases already exist for prescription painkillers
Compounded GLP-1s Are Not FDA-Approved Jorge Moreno, MD, an assistant professor and obesity medicine doctor at Yale Medicine in New Haven, Connecticut, says the findings highlight a broader concern that obesity specialists have about compounded versions of GLP-1 medications
Chronobiol Int (2013) 30(9):114459
